-
Lupin introduces its first brand in the US -
Suprax ®
-
Lupin receives approval for its first ANDA -
cefuroxime axetial
- ANDA filed with the USFDA for
cefixime, cefuroxime axetil
- ANDA filed with the USFDA for
cefotaxime and ceftriaxone
- State-of-the art Lupin R&D
center is commissioned at
Pune
- Oral
cephalosporin bulk actives
plant is commissioned
- Commences
cephalosporin bulk actives
supplies to partners
in the US
- Lupin
Labs and Lupin Chemicals
amalgamated to form Lupin
Limited
- The Cefotaxime facility is approved by the
USFDA
- The Company's
restructuring operations yield
encouraging results
- UK MCA approval for injectable cephalosporin bulk actives
plant
- USFDA approval for 3 plants manufacturing
Cefaclor, 7 ADCA and
Rifampicin
- UK MCA approval granted for Lupin's injectable cephalosporins
dosages plant. MCC (South Africa) approves formulations facility
at
Aurangabad
- The best exporter award conferred by
GOI. The company receives
the ICMA technology award for injectable
cephalosporins
- Lupin Labs and Lupin Chemicals raise money through an
IPO. The
sterile plant for injectable cephalosporins (bulk) is
commissioned
- Lupin Labs and Lupin Chemicals raise money through an
IPO. The
sterile plant for injectable cephalosporins (bulk) is
commissioned
- The fermentation plant of Lupin Chemicals is
established
- Injectable cephalosporin (bulk and dosages) production initiated. Two
plants receive approvals for maintaining stringent standards laid down
by the
USFDA. The group secures the ICMA technology award for the
successful manufacture of vitamin
B6
- JV in Thailand - Lupin Chemicals (Thailand) Ltd
established
- Cephalexin and 7 ADCA plants go on
stream
- Ankleshwar Plant commissioned for manufacture of
Ethambutol
- R&D recognition by Department of Science &
Technology
- Lupin commences Ethambutol production; becomes one of the
largest producers in the world with a market share of
80%
- Lupin Group commissions a formulations plant and R&D centre in
Aurangabad
